US Reimbursement Coverage

Deltex Medical Group PLC
23 May 2007

                            Deltex Medical Group plc



US Centers for Medicare & Medicaid Services issues final decision memorandum on
                 reimbursement coverage for oesophageal Doppler





23 May 2007 - Deltex Medical Group plc ('Deltex Medical' or 'Company'), the UK's
leading haemodynamic monitoring company, today notes the publication of the
final decision memorandum by the US Centers for Medicare & Medicaid Services
(CMS) confirming that coverage will be implemented on a national basis for
reimbursement of the use of oesophageal Doppler monitoring to guide fluid
therapy in ventilated patients in intensive care and for all patients undergoing
surgery requiring fluid management.


The Company will issue a further, detailed statement on this in due course, once
it has had an opportunity to review the CMS statement in full and consulted with
its advisors in the USA.



The full text of the decision memo is available on line at the CMS website:

https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=196



For further information, please contact:-

Deltex Medical Group plc                     1243 774 837
Nigel Keen, Chairman                         [e-mail]
Andy Hill, Chief Executive                   [e-mail]
Ewan Phillips, Finance Director              [e-mail]


Gavin Anderson & Company                     0207 554 1400
Deborah Walter                               [e-mail]
Robert Speed                                 [e-mail]


Charles Stanley Securities                   020 7149 6457
Philip Davies                                [e-mail]
Russell Cook                                 [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM) monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.


There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


  • Validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works


  • Proved that the CardioQ works in a wide range of surgical procedures


  • Demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.


                      This information is provided by RNS
            The company news service from the London Stock Exchange